Enamine Plsp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2023-05-18
Share capital
5 000,00 PLN
Activity description

Enamine Pl supplies compound libraries, building blocks and screening collections for drug discovery. Its services include custom and library synthesis, CADD, biology support and integrated drug discovery.

Registered address
al. Kasztanowa 3A-5, 53-125 Wrocław, Poland
Website
enamine.netWebsite active
Phone
Social media
Electronic delivery address
AE:PL-11562-18115-AGCAW-18

Financials

Revenue history (in k)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 2.21mMedianUSD 38.54kAverageUSD 2.32m
Net profit
This companyUSD -478.10kMedianUSD -1.56kAverageUSD -88.44k
Operating costs
This companyUSD 2.47mMedianUSD 56.03kAverageUSD 2.29m
Assets
This companyUSD 1.28mMedianUSD 119.99kAverageUSD 2.73m

News

Enamine and Ewha Partner to Close the Loop Between AI Design and Real-World Chemistry

Enamine and Ewha Partner to Close the Loop Between AI Design and Real-World Chemistry

Strategic MOU connects AI-driven design with billions of make-on-demand molecules, rapid synthesis and in-house biology, and builds a new scientific bridge between Korea and Ukraine

SyntheticGestalt and Enamine Build the World’s Largest Experimentally Validated AI-driven Chemical Data Ecosystem

Tokyo, Japan, and Kyiv, Ukraine — 3 August 2026

ANTARES project launch: Artificial Intelligence aims to speed up the search for new antibacterials

Braunschweig, Frankfurt, Hamburg, Germany – July 23, 2026

Leveraging Public Infrastructure for Private Innovation: Enamine and PAL Align

Collaboration leverages PAL’s public research facilities and Enamine’s compound libraries and fragment progression support to accelerate fragment-based lead discovery (FBLD).

Enamine Strengthens Its Sustainable Procurement Program in 2026

In 2026, Enamine’s Sustainable Procurement Program is reaching a new level of maturity and impact. Building on many years of close cooperation with suppliers – and reinforced by global best practices – the Company is further strengthening its approach to responsible and sustainable procurement across the entire supply chain.

Chemspace, Enamine, and Paul Scherrer Institute Launch a Joint Service for Fragment-Based Lead Discovery

Kyiv, Ukraine and Villigen, Switzerland , April 7, 2026. Chemspace, a drug discovery engine providing machine learning-guided support for hit identification, hit to lead, and lead optimization using the largest purchasable collection of chemicals and biologics, Enamine, a leading provider of small molecules and drug discovery services, and the Paul Scherrer Institute (PSI), the largest research institute for natural and engineering sciences in Switzerland, have announced today a strategic…

Bank accounts

Registered as a VAT taxpayer on 2023-05-24. Active

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Public aid

No public aid cases recorded in the last 10 years.

Tenders

No recorded participation in tenders.

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Authorized Representatives

Petro Borysko – Management Board Member
Zbigniew Marek Darżynkiewicz – President of the Management Board
Michał Piróg – Management Board Member

Manner of representation

The company is represented by each member of the management board acting independently.

Ownership

OwnerSharesShare valueStake
Zbigniew Marek Darżynkiewicz (46)
5$67.535%
Naukovo-Vyrobnyche Pidpryiemstvo Yenamin” Tovarystvo Z Obmezhenoiu Vidpovidalnistiu
95$1,283.0995%

Beneficial owners

Person

Competitors

Name
MabionS.A.
Aslab ScienceP.S.A.

FAQ

Last updated: 2026-06-25